DR. DANIEL ROY WEINBERGER, M.D.
Neurology at Davenport St, Washington, DC
License number
DC MD11085
Category
Neurology
Type
Neurology
Address
Address
3116 Davenport St NW, Washington, DC 20008
Phone
(202) 415-6404
Professional information
Phosphatidylinositol-3-Kinase P110 Delta-Targeted Drugs In The Treatment Of Cns Disorders
US Patent:
2011029, Dec 1, 2011
Filed:
Dec 4, 2009
Appl. No.:
13/132425
Inventors:
Amanda J. Law - Washington DC, US
Daniel R. Weinberger - Washington DC, US
Daniel R. Weinberger - Washington DC, US
International Classification:
A61K 31/5377, A61K 31/506, A61K 31/427, A61K 31/519, A61P 25/18, A61K 31/4985, C12Q 1/68, G01N 33/566, C12Q 1/02, A61P 25/00, A61K 31/52, A61K 31/498
US Classification:
5142342, 51426321, 51426322, 514275, 514371, 5142621, 514249, 5142348, 435 611, 435 71, 435 29
Abstract:
Methods for treating CNS disorders such as schizophrenia, psychosis and cognitive disorders using specific inhibitors of phosphatidylinositol-3-kinase p110 delta (PIK3CD) expression and/or activity are described. Methods of determining risk of CNS disorders and methods of determining treatment response are also described. An integrative systems biology approach to identify a signaling mechanism and genetic network associated with schizophrenia and with schizophrenia-associated risk variation in ErbB4. A risk pathway associated with ErbB4 genetic variation involving increased expression of a PI3K-linked ErbB4 receptor CYT-1 and a specific PI3K enzyme, PIK3CD has been identified.
Dr. Daniel R Weinberger, Washington DC - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Neurology), Neuropsychiatry (Psychiatry)
Address:
WEINBERGER, DANIEL R MD
3116 Davenport St NW STE NW, Washington 20008
(202) 363-6404 (Phone)
3116 Davenport St NW STE NW, Washington 20008
(202) 363-6404 (Phone)
Certifications:
Neurology, 1984, Psychiatry, 1978
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Perelman School of Medicine University of Pennsylvania
Graduated: 1973
Harbor Genl Hosp
George Washington University
Mass Mh Ctr
University Of California-Los Angeles
Perelman School of Medicine University of Pennsylvania
Graduated: 1973
Harbor Genl Hosp
George Washington University
Mass Mh Ctr
University Of California-Los Angeles
Stannylated 3-Quinuclidinyl Benzilates And Methods Of Preparing Radiohalogenated Derivatives
US Patent:
5569447, Oct 29, 1996
Filed:
Apr 19, 1994
Appl. No.:
8/229837
Inventors:
Kan S. Lee - Rockville MD
Daniel R. Weinberger - Washington DC
Daniel R. Weinberger - Washington DC
Assignee:
The United States of America represented by the Secretary Department of
Health and Human Services - Washington DC
Health and Human Services - Washington DC
International Classification:
A61K 5104, C07D45302, A01N 4390
US Classification:
424 185
Abstract:
The present invention provides stannylated 3-quinuclidinyl benzilate compounds and a method of synthesizing *AQNB by iodinating such stannylated 3-quinuclidinyl benzilate compounds. The iodination of these stannylated 3-quinuclidinyl benzilates proceeds in as little as five minutes; thus, the stannylated 3-quinuclidinyl benzilates may be converted to *AQNB in situ for immediate use. Using this method, radiolabelling yields as high as 80% have been observed. The present invention also is directed towards a method of synthesis of the stannylated 3-quinuclidinyl benzilate compounds. The method comprises providing a 4'-halo-3-quinuclidinyl benzilate and reacting the 4'-halo-3-quinuclidinyl benzilate with a compound having the formula (SnR. sub. 3). sub. 2, wherein R is an alkyl.
Schizophrenia-Related Isoform Of Kcnh2 And Development Of Antipsychotic Drugs
US Patent:
8101380, Jan 24, 2012
Filed:
Mar 21, 2008
Appl. No.:
12/593159
Inventors:
Daniel R. Weinberger - Washington DC, US
Stephen J. Huffaker - Crawfordsville IN, US
Joel E. Kleinman - Washington DC, US
Bai Lu - Bethesda MD, US
Stephen J. Huffaker - Crawfordsville IN, US
Joel E. Kleinman - Washington DC, US
Bai Lu - Bethesda MD, US
Assignee:
The United States of America as represented by the Secretary of Health and Human Services - Washington DC
International Classification:
C12P 21/06, C12N 15/00, C07K 1/00, C07H 21/02, C07H 21/04
US Classification:
435 691, 4353201, 530350, 536 231, 536 235
Abstract:
The invention is related to a novel primate specific brain isoform of the potassium channel KCNH2 and genetic association with risk for schizophrenia.
Effect Of Comt Genotype On Frontal Lobe Function
US Patent:
2003010, May 29, 2003
Filed:
May 10, 2002
Appl. No.:
10/144000
Inventors:
Daniel Weinberger - Washington DC, US
Michael Egan - Chevy Chase MD, US
Terry Goldberg - Bethesda MD, US
Joseph Callicott - Bethesda MD, US
David Goldman - Potomac MD, US
Michael Egan - Chevy Chase MD, US
Terry Goldberg - Bethesda MD, US
Joseph Callicott - Bethesda MD, US
David Goldman - Potomac MD, US
International Classification:
A61K031/00, C12Q001/68
US Classification:
514/001000, 435/006000
Abstract:
The invention provides a method of detecting impaired prefrontal cognitive function in an individual by determining the individual's COMT genotype, and associating a high activity Val allele with impaired prefrontal cognitive function (and a low activity Met allele with enhanced prefrontal cognitive function).
Effect Of Bdnf Genotype On Hippocampal Function And Verbal Memory And Risk For Schizophrenia
US Patent:
2005001, Jan 20, 2005
Filed:
Feb 27, 2004
Appl. No.:
10/789169
Inventors:
Daniel Weinberger - Washington DC, US
Michael Egan - Chevy Chase MD, US
Bhaskar Kolachana - Oakton VA, US
David Goldman - Potomac MD, US
Joseph Callicott - Bethesda MD, US
Terry Goldberg - Bethesda MD, US
Michael Egan - Chevy Chase MD, US
Bhaskar Kolachana - Oakton VA, US
David Goldman - Potomac MD, US
Joseph Callicott - Bethesda MD, US
Terry Goldberg - Bethesda MD, US
International Classification:
C12Q001/68
US Classification:
435006000
Abstract:
The invention is related to the discovery that a met66val polymorphism in the gene for brain-derived neurotrophic factor (BDNF) is correlated with hippocampal function and verbal memory and risk for neuropsychiatric disorders such as schizophrenia.
Effect Of Comt Genotype On Frontal Lobe Function
US Patent:
2006016, Jul 27, 2006
Filed:
Mar 31, 2006
Appl. No.:
11/395043
Inventors:
Daniel Weinberger - Washington DC, US
Michael Egan - Chevy Chase MD, US
Terry Goldberg - Bethesda MD, US
Joseph Callicott - Bethesda MD, US
David Goldman - Potomac MD, US
Michael Egan - Chevy Chase MD, US
Terry Goldberg - Bethesda MD, US
Joseph Callicott - Bethesda MD, US
David Goldman - Potomac MD, US
International Classification:
C12Q 1/68
US Classification:
435006000
Abstract:
The invention provides a method of detecting impaired prefrontal cognitive function in an individual by determining the individual's COMT genotype, and associating a high activity Val allele with impaired prefrontal cognitive function (and a low activity Met allele with enhanced prefrontal cognitive function).
Schizophrenia-Related Isoform Of Kcnh2 And Development Of Antipsychotic Drugs
US Patent:
2012019, Jul 26, 2012
Filed:
Jan 24, 2012
Appl. No.:
13/357416
Inventors:
Daniel R. WEINBERGER - Washington DC, US
Assignee:
THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES - Bethesda MD
International Classification:
C12Q 1/68, C40B 30/00, H01J 49/26, G01N 33/559, G01N 27/447, G01N 33/566, C40B 20/00
US Classification:
506 2, 435 611, 435 792, 436501, 506 7, 435 612, 435 71, 204456, 250282
Abstract:
The invention is related to a novel primate specific brain isoform of the potassium channel KCNH2 and genetic association with risk for schizophrenia and response to therapy.
Rat Or Mouse Exhibiting Behaviors Associated With Human Schizophrenia
US Patent:
5549884, Aug 27, 1996
Filed:
Oct 28, 1992
Appl. No.:
7/967367
Inventors:
Daniel R. Weinberger - Washington DC
Barbara K. Lipska - Annandale VA
George E. Jaskiw - Lyndhurst OH
Barbara K. Lipska - Annandale VA
George E. Jaskiw - Lyndhurst OH
Assignee:
The United States of America as represented by the Secretary of the
Department of Health and Human Services - Washington DC
Department of Health and Human Services - Washington DC
International Classification:
A61K 4900, C12N 1500, G01N 3700
US Classification:
424 92
Abstract:
This invention provides a unique and surprisingly accurate animal model for human schizophrenia. The animals are brain damaged while prepubescent. The brain damage consists of a ventral hippocampus lesion induced by exposure of the hippocampus region to a neurotoxin. When the animal reaches puberty, abnormal behavior and a number of biological phenomena associated with schizophrenic symptoms emerge. These animals are useful for assaying pharmaceutical compounds for anti-schizophrenic activity.